JP2021501800A5 - - Google Patents

Info

Publication number

JP2021501800A5

JP2021501800A5 JP2020543732A JP2020543732A JP2021501800A5 JP 2021501800 A5 JP2021501800 A5 JP 2021501800A5 JP 2020543732 A JP2020543732 A JP 2020543732A JP 2020543732 A JP2020543732 A JP 2020543732A JP 2021501800 A5 JP2021501800 A5 JP 2021501800A5

Authority

JP

Japan

Prior art keywords

composition

antibody drug

drug conjugate

administered

cell lymphoma

Prior art date

2018-11-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims 28
• 239000000611 antibody drug conjugate Substances 0.000 claims 20
• 229940049595 antibody-drug conjugate Drugs 0.000 claims 20
• 238000002648 combination therapy Methods 0.000 claims 15
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 14
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 13
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 13
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 11
• 230000004936 stimulating effect Effects 0.000 claims 9
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 7
• 229960004397 cyclophosphamide Drugs 0.000 claims 7
• 229960004679 doxorubicin Drugs 0.000 claims 7
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 7
• 238000002512 chemotherapy Methods 0.000 claims 6
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 5
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 5
• 210000003714 granulocyte Anatomy 0.000 claims 4
• 108091005804 Peptidases Proteins 0.000 claims 3
• 239000004365 Protease Substances 0.000 claims 3
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
• 206010042971 T-cell lymphoma Diseases 0.000 claims 3
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
• 230000000977 initiatory effect Effects 0.000 claims 3
• 238000000034 method Methods 0.000 claims 3
• 229960004618 prednisone Drugs 0.000 claims 3
• 108010016626 Dipeptides Proteins 0.000 claims 2
• 206010025323 Lymphomas Diseases 0.000 claims 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 2
• 229960000455 brentuximab vedotin Drugs 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 201000005787 hematologic cancer Diseases 0.000 claims 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
• 208000015181 infectious disease Diseases 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 claims 1
• 208000007433 Lymphatic Metastasis Diseases 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 206010034580 Peripheral motor neuropathy Diseases 0.000 claims 1
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
• 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 claims 1
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 229960002173 citrulline Drugs 0.000 claims 1
• 208000037902 enteropathy Diseases 0.000 claims 1
• 230000001747 exhibiting effect Effects 0.000 claims 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
• 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims 1
• 208000028774 intestinal disease Diseases 0.000 claims 1
• 108010093470 monomethyl auristatin E Proteins 0.000 claims 1
• 201000002239 motor neuritis Diseases 0.000 claims 1
• 201000005545 motor peripheral neuropathy Diseases 0.000 claims 1
• 208000004235 neutropenia Diseases 0.000 claims 1
• 230000002093 peripheral effect Effects 0.000 claims 1
• 208000033808 peripheral neuropathy Diseases 0.000 claims 1
• 201000006845 reticulosarcoma Diseases 0.000 claims 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
• 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
• 125000006850 spacer group Chemical group 0.000 claims 1
• 230000002792 vascular Effects 0.000 claims 1